1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. News
  7. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
321.23 USD   +1.62%
05/20DEXCOM INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/17Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating
MT
05/11TRANSCRIPT : DexCom, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 02:40 PM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Dexcom

01/21/2022 | 06:42am EDT


© MT Newswires 2022
All news about DEXCOM, INC.
05/20DEXCOM INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/17Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating
MT
05/11TRANSCRIPT : DexCom, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2..
CI
05/10Dexcom Announces Upcoming Conference Presentations
BU
04/29Raymond James Adjusts DexCom's Price Target to $486 From $538, Keeps Outperform Rating
MT
04/29Morgan Stanley Adjusts Price Target for DexCom to $492 From $514, Maintains Equalweigh..
MT
04/29SVB Leerink Adjusts DexCom's Price Target to $500 From $565, Keeps Outperform Rating
MT
04/29Piper Sandler Adjusts DexCom's Price Target to $480 From $725, Reiterates Overweight Ra..
MT
04/28DEXCOM : Reports First Quarter 2022 Financial Results - Form 8-K
PU
04/28DEXCOM INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF ..
AQ
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Financials (USD)
Sales 2022 2 917 M - -
Net income 2022 380 M - -
Net cash 2022 63,8 M - -
P/E ratio 2022 86,4x
Yield 2022 -
Capitalization 31 521 M 31 521 M -
EV / Sales 2022 10,8x
EV / Sales 2023 8,98x
Nbr of Employees 6 300
Free-Float 99,5%
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 321,23 $
Average target price 528,29 $
Spread / Average Target 64,5%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain Chief Financial Officer & EVP-Finance
Andrew K. Balo EVP-Global Medical Affairs, Access & Evidence
Jacob S. Leach Chief Technology Officer & Executive VP
Donald M. Abbey Executive VP-IT, Quality & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.-40.18%31 521
ABBOTT LABORATORIES-19.54%196 876
MEDTRONIC PLC-0.89%137 843
BECTON, DICKINSON AND COMPANY2.66%71 591
BAXTER INTERNATIONAL INC.-14.69%36 556
HOYA CORPORATION-26.33%36 134